Stock · SOLV · Healthcare
United States · Large Cap · listed since 2024 · Revenue 12 mo. $8.3B
Price as of 11/06/2026
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally.
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
Original text from the data provider
Summary
50.9 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
5 more unchanged: Revenue, 12 mo., EBIT margin, Net debt, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 30.82% | 11.52% | Rank 86 |
| Return on capital (Greenblatt) | 106.44% | 32.55% | Rank 93 |
| EBIT margin | 26.20% | 18.31% | Rank 74 |
| FCF margin | −0.12% | 14.12% | Rank 6 |
| Gross margin | 53.47% | 60.99% | Rank 40 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 0.86% | 8.04% | Rank 15 |
| Earnings growth, 3 years per year | 4.46% | 5.44% | Rank 47 |
| Earnings growth, 5 years per year | 6.11% | 7.00% | Rank 46 |
| Sustainable growth (ROE × retained earnings) | 4.55% | 3.66% | Rank 57 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 9.82% | 2.90% | Rank 99 |
| FCF yield | −0.06% | 3.63% | Rank 7 |
| EV/saleslower is better | 2.39 | 4.03 | Rank 70 |
| EV/EBITlower is better | 9.14 | 21.73 | Rank 98 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 26.75% | 8.66% | Rank 76 |
| Share price, 6 months | 23.65% | 24.27% | Rank 49 |
| Share price, 3 months | 14.05% | 15.42% | Rank 47 |
| Distance from 52-week high | −2.23% | −7.35% | Rank 73 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −11.20% | 0.30% | Rank 92 |
| Change in share countlower is better | 0.92% | 0.00% | Rank 14 |
| Dividend streak in yearsdoes not count towards the rank | – | 10 | |
| Price reaction to results, market-adjusted | −4.91% | 0.05% | Rank 12 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 35.32% | 48.40% | Rank 25 |
| Net debt/EBITDAlower is better | 1.63 | 1.11 | Rank 41 |
| Debt to equitylower is better | 1.00 | 0.48 | Rank 20 |
| Volatility, 1 yearlower is better | 30.84% | 31.42% | Rank 55 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt |
|---|---|---|---|---|---|
| 2020 | 7.3 | 19.6% | $1.8B | 172M | – |
| 2021 | 8.2 | 23.0% | $1.9B | 172M | $21.0M |
| 2022 | 8.1 | 20.8% | $1.4B | 172M | $34.0M |
| 2023 | 8.2 | 20.6% | $1.6B | 173M | $8.1B |
| 2024 | 8.3 | 12.6% | $805.0M | 174M | $7.2B |
| 2025 | 8.3 | 26.2% | −$10.0M | 175M | $4.2B |
3 of 7 StockScorer Score rules met · How the score is built
Solventum Corp. mainly meets criteria in the Momentum category. Result from 18 strategies checked.
Solventum Corp. is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
4 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Solventum Corp.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 10.2 | 30.0 |
| P/B ratio | 3.1 | 4.8 |
| Return on equity (ROE) | 30.8% | 11.5% |
| Equity ratio | 35.3% | 48.4% |
| Debt-to-equity (D/E) | 1.00 | 0.48 |
| Dividend yield | – | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| SOLV | Solventum Corp.this page | |
| BAX | Baxter International Inc | Low0.9 |
| RGEN | Repligen Corporation | locked |
| COO | The Cooper Companies, Inc | Low1.8 |
| ALGN | Align Technology Inc | locked |
| WST | West Pharmaceutical Services Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.